Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
82,815,631
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
29,839,293
-
Shares change
-
+7,704,826
-
Total reported value, excl. options
-
$365,363,130
-
Value change
-
+$94,551,507
-
Put/Call ratio
-
43%
-
Number of buys
-
57
-
Number of sells
-
-20
-
Price
-
$12.24
Significant Holders of EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) as of Q4 2021
96 filings reported holding EYPT - EyePoint Pharmaceuticals, Inc. - Common Stock as of Q4 2021.
EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29,839,293 shares
of 82,815,631 outstanding shares and own 36.03% of the company stock.
Largest 10 shareholders include FRANKLIN RESOURCES INC (4,947,165 shares), Essex Woodlands Management, Inc. (4,190,921 shares), RA CAPITAL MANAGEMENT, L.P. (3,370,506 shares), SUVRETTA CAPITAL MANAGEMENT, LLC (2,519,700 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1,950,000 shares), JANUS HENDERSON GROUP PLC (1,671,183 shares), CITADEL ADVISORS LLC (1,469,213 shares), BlackRock Inc. (1,440,631 shares), VANGUARD GROUP INC (1,188,970 shares), and GOLDMAN SACHS GROUP INC (622,018 shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.